Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease

Author： Reese Jens P   Dams Judith   Winter Yaroslav   Balzer-Geldsetzer Monika   Oertel Wolfgang H   Dodel Richard  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.7, 2012-05, pp. : 939-958

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoeconomic Considerations in Treating Patients With Acute Leukaemia

By Jønsson V.  

PharmacoEconomics, Vol. 15, Iss. 2, 1999-02 ,pp. : 167-178

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the US: A Literature Review

By Zhang Bin  

PharmacoEconomics, Vol. 29, Iss. 6, 2011-06 ,pp. : 461-474

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic Considerations in Treating Actinic Keratosis

By Neidecker Marjorie V.  

PharmacoEconomics, Vol. 27, Iss. 6, 2009-06 ,pp. : 451-464

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic Considerations in Treating Ovarian Cancer

By Bodurka-Bevers D.   Sun C.C.   Gershenson D.M.  

PharmacoEconomics, Vol. 17, Iss. 2, 2000-02 ,pp. : 133-150

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease

By Brophy Donald F   Ripley Elizabeth BD   Holdford David A  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 9, 2003-09 ,pp. : 1461-1469

Informa Healthcare

Access to resources Recommend Favorite